Enterome to Attend the Jefferies 2018 Global Healthcare Conference in New York

Monday, June 4, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

PARIS and CAMBRIDGE, Ma., June 4, 2018 /PRNewswire/ --

Enterome SA, a clinical-stage biotechnology

company pioneering innovative therapies to treat microbiome-associated diseases with a focus on inflammatory bowel diseases (IBD) and immuno-oncology (IO) indications, will attend the Jefferies 2018 Global Healthcare Conference. The conference will be
held in New York, June 5-8 and features an extensive range of public and private healthcare companies across the Biopharmaceuticals, Life Sciences, Healthcare Services, Healthcare IT and Medical Technology sectors. It hosted over 2,600 attendees in 2017.

About Enterome 

Enterome is pioneering the development of novel pharmaceuticals and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD) and cancer.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.

Enterome has established partnerships with leading pharmaceutical companies and academic research institutes, including Johnson & Johnson Innovation/Janssen Biotech, Takeda and Abbvie in inflammatory bowel and gastro-intestinal diseases; and Bristol-Myers Squibb in immuno-oncology.

Enterome also has a 50/50 joint venture with Nestlé Health Science, called Microbiome Diagnostics Partners, focused initially on the development of novel microbiome-based diagnostics for IBD and liver diseases.

The Company was established in 2012 in Paris (France) to develop the discoveries made by the INRA metagenomic platform, and is backed by leading venture capital investors (Seventure Partners, Lundbeckfonden Ventures, Health for Life Capital, Omnes Capital and Principia) and strategic investors (BMS, Nestlé Health Science, Shire & INRA Transfert).

Additional information about Enterome is available through its website: www.enterome.com

Contacts 

Pierre Belichard, CEO pbelichard@enterome.com

Media relations 

Mark Swallow / Marine Perrier / David Dible Citigate Dewe Rogerson Tel. +44-207-638-9571 enterome@citigatedewerogerson.com

Investor relations 

Lisa Pavelka Rx Communications Group Tel. +1-917-843-0223 lpavelka@rxir.com

SOURCE Enterome



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store